adagrasib
mirati
['krystal-1', 'sclc', 'nsclc']
results from the krystal-1 study in previously treated kras g12c nsclc patients. 80% dcr, ic dcr 85%, median os 12.6 mo [9.2-19.2].
nice result in this setting although, overall, anti-kras remains disapointing as compared to other targeted therapies in nsclc. #asco22 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????